Plough­ing through a crowd­ed PD-(L)1 mar­ket, BeiGene loads up on promis­ing lung can­cer da­ta

6 years ago
R&D
China

Mod­er­na's mis­sion to spear­head a rev­o­lu­tion in vac­cine R&D comes cen­ter stage to­day as the world faces a cru­cial ...

6 years ago
R&D
Coronavirus

FDA re­ports more short­ages of drugs used to put Covid-19 pa­tients on ven­ti­la­tors

6 years ago
FDA+
Coronavirus

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

6 years ago
R&D
Coronavirus

Q&A: An­a­lyst-turned biotech ex­ec-turned an­a­lyst reads the biotech Q1 tea leaves

6 years ago
People
R&D

'Why not do it now?' Al­ny­lam's John Maraganore takes up Black­stone's $2B of­fer to build the fi­nal 'bridge to ...

6 years ago
Deals

Covid-19 roundup: Tri­al of Trump's fa­vorite Covid-19 drug nixed on ear­ly death risk; Is An­tho­ny Fau­ci on thin ice ...

6 years ago
Coronavirus

How you can help us grow End­points News through the pan­dem­ic

6 years ago
Publisher's note

As­traZeneca stops lung can­cer tri­al ear­ly, af­ter star drug Tagris­so in­duces 'over­whelm­ing' ef­fi­ca­cy

6 years ago
R&D

Judge slaps en­hanced dam­ages on Gilead/Kite for ‘will­ful’ patent vi­o­la­tion, boost­ing award to a block­buster $1.2B ...

6 years ago
R&D

As­traZeneca, Mer­ck win quick OK for a rare dis­ease drug — as the FDA de­clares it can still move fast dur­ing a ...

6 years ago
Pharma
FDA+

A small remde­sivir study with lots of short­com­ings sug­gests it may be work­ing against Covid-19 — and 1 an­a­lyst ...

6 years ago
R&D
Coronavirus

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

6 years ago
R&D
Coronavirus

Pfiz­er nabs col­orec­tal can­cer OK for Braftovi; Bris­tol My­ers, Pfiz­er pull out of re­gion­al deal with Por­to­la

6 years ago
News Briefing

A bruised Cir­cas­sia of­floads debt by re­turn­ing COPD drugs to As­traZeneca

6 years ago
Deals

Covid-19 Track­er up­dates vac­cine can­di­dates

6 years ago
FDA+
Coronavirus

Tan­go Ther­a­peu­tics nabs $60M in CRISPR-based hunt for hid­den can­cer genes

6 years ago
Financing
R&D

Hunt­ing a full OK for Baven­cio in front­line blad­der can­cer, Pfiz­er, Mer­ck KGaA re­ceive VIP treat­ment at FDA

6 years ago
Pharma
FDA+

Fred­er­ic Pla en­list­ed as COO at the Park­er In­sti­tute; For­mer Alk­er­mes ex­ec named CMO at Seres Ther­a­peu­tics

6 years ago
Peer Review

Covid-19 roundup: Pfiz­er hus­tling up mil­lions of dos­es of vac­cine — de­tails $748M BioN­Tech deal; CDC tweaks stance ...

6 years ago
Coronavirus

Qim­ing's Chi­na-fo­cused $1.1B new fund brings glob­al haul to $5B with­in 1 week — but the dis­tri­b­u­tion won't be even

6 years ago
Financing
China

Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size ...

6 years ago
R&D
Coronavirus

Keytru­da nabs an­oth­er pri­or­i­ty re­view; Quell ties up CAR pact with Han­nover Med­ical School

6 years ago
News Briefing

Com­pound­ing drugs dur­ing the pan­dem­ic: FDA of­fers pol­i­cy clar­i­fi­ca­tions

6 years ago
FDA+
First page Previous page 845846847848849850851 Next page Last page
A service from the Financial Times